Charles River Laboratories International (CRL) Stock Analysis & Winston Score

Charles River Laboratories helps pharmaceutical and biotech companies develop new drugs and medicines. It does this by providing laboratory animals used in early-stage research, running safety and toxicology tests, and offering contract research services. Its main customers are large drug companies, biotech startups, and government agencies that need outside help testing whether a drug is safe before it reaches human trials. The company earns money by charging fees for research services, animal sales, and laboratory testing contracts. It operates globally, with facilities across North America, Europe, and Asia, and generates roughly $4 billion in annual revenue. Its competitive moat comes from deep regulatory expertise, long-term client relationships, and the high cost and complexity of replicating its specialized facilities. The main risk the business faces is that biotech funding has tightened significantly in recent years, causing drug companies to cut outsourced research spending — which directly pressures Charles River's revenue and margins.